» Articles » PMID: 36864910

White Matter Hyperintensities in Cholinergic Pathways Are Associated with Dementia Severity in E4 Carriers but Not in Non-carriers

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Mar 3
PMID 36864910
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Among individuals with Alzheimer's disease (AD), e4 carriers with increased white matter hyperintensities (WMHs) may selectively be at increased risk of cognitive impairment. Given that the cholinergic system plays a crucial role in cognitive impairment, this study aimed to identify how status modulates the associations between dementia severity and white matter hyperintensities in cholinergic pathways.

Methods: From 2018 to 2022, we recruited participants ( e4 carriers, = 49; non-carriers, = 117) from the memory clinic of Cardinal Tien Hospital, Taipei, Taiwan. Participants underwent brain MRI, neuropsychological testing, and genotyping. In this study, we applied the visual rating scale of the Cholinergic Pathways Hyperintensities Scale (CHIPS) to evaluate WMHs in cholinergic pathways compared with the Fazekas scale. Multiple regression was used to assess the influence of CHIPS score and carrier status on dementia severity based on Clinical Dementia Rating-Sum of Boxes (CDR-SB).

Results: After adjusting for age, education and sex, higher CHIPS scores tended to be associated with higher CDR-SB in e4 carriers but not in the non-carrier group.

Conclusions: Carriers and non-carriers present distinct associations between dementia severity and WMHs in cholinergic pathways. In e4 carriers, increased white matter in cholinergic pathways are associated with greater dementia severity. In non-carriers, WMHs exhibit less predictive roles for clinical dementia severity. WMHs on the cholinergic pathway may have a different impact on e4 carriers vs. non-carriers.

Citing Articles

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.

Lane R, Darreh-Shori T, Junge C, Li D, Yang Q, Edwards A BMC Neurol. 2024; 24(1):116.

PMID: 38594621 PMC: 11003149. DOI: 10.1186/s12883-024-03611-5.


Intelligent cholinergic white matter pathways algorithm based on U-net reflects cognitive impairment in patients with silent cerebrovascular disease.

Fei B, Cheng Y, Liu Y, Zhang G, Ge A, Luo J Stroke Vasc Neurol. 2024; 9(6):699-707.

PMID: 38569895 PMC: 11791635. DOI: 10.1136/svn-2023-002976.

References
1.
OBryant S, Waring S, Cullum C, Hall J, Lacritz L, Massman P . Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008; 65(8):1091-5. PMC: 3409562. DOI: 10.1001/archneur.65.8.1091. View

2.
Wardlaw J, Smith E, Biessels G, Cordonnier C, Fazekas F, Frayne R . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12(8):822-38. PMC: 3714437. DOI: 10.1016/S1474-4422(13)70124-8. View

3.
Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

4.
Liu Q, Zhu Z, Teipel S, Yang J, Xing Y, Tang Y . White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. Front Aging Neurosci. 2017; 9:47. PMC: 5326769. DOI: 10.3389/fnagi.2017.00047. View

5.
Schliebs R, Arendt T . The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna). 2006; 113(11):1625-44. DOI: 10.1007/s00702-006-0579-2. View